# Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

> **NCT03606369** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Instituto Nacional de Cancerologia de Mexico** · enrollment: 560 (estimated)

## Conditions studied

- Breast Neoplasm
- Antineoplastic Agents
- Antiemetics
- Quality of Life

## Interventions

- **DRUG:** Palonosetron
- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT03606369
- **Lead sponsor:** Instituto Nacional de Cancerologia de Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11-05
- **Primary completion:** 2018-07-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606369, "Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03606369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*